Emerald Advisers Portfolio holdings
Top Buys
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$30.5M |
| 2 |
AdaptHealth
AHCO
|
+$26.6M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$19.6M |
| 4 |
BJ's Restaurants
BJRI
|
+$17.7M |
| 5 |
SI
Silvergate Capital Corporation
SI
|
+$16.5M |
Top Sells
| 1 |
MNTV
Momentive Global Inc. Common Stock
MNTV
|
+$35.4M |
| 2 |
New Fortress Energy
NFE
|
+$28.3M |
| 3 |
Immunovant
IMVT
|
+$27.9M |
| 4 |
Karyopharm Therapeutics
KPTI
|
+$25M |
| 5 |
Taylor Morrison
TMHC
|
+$23.8M |
Sector Composition
| 1 | Healthcare | 22.04% |
| 2 | Technology | 19.82% |
| 3 | Consumer Discretionary | 16.91% |
| 4 | Industrials | 13.94% |
| 5 | Financials | 11.67% |
Similar funds
Emerald Advisers's Q1 2021 Portfolio in Review
As of Q1 2021, Emerald Advisers held 319 positions worth $2.77B, down 8% from $3.01B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Emerald Advisers withdrew a net $349M in Q1 2021, closing 77 positions and reducing 134 holdings. Its most notable exit was Momentive Global Inc. Common Stock, an estimated $35.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 23% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Emerald Advisers opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $26.1M.
- Emerald Advisers's largest Q1 2021 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 261,467 shares worth $26.1M.
- Emerald Advisers added most to AdaptHealth in Q1 2021, an estimated $26.6M increase.
- Emerald Advisers's biggest Q1 2021 reduction was New Fortress Energy, cutting an estimated $28.3M.
- Emerald Advisers fully exited Momentive Global Inc. Common Stock in Q1 2021, selling an estimated $35.4M.
- Emerald Advisers's ten largest holdings make up 18% of its $2.77B portfolio in Q1 2021.
- Emerald Advisers opened 33 new positions and closed 77 in Q1 2021.
- Emerald Advisers's portfolio value fell 8% quarter-over-quarter to $2.77B.
Based on Emerald Advisers's 13F filing for Q1 2021, filed 29 Apr 2021.